Hoechst Aktiengesellschaft

Novartis Ag

Universitat Ulm

Elbe Technologies Ltd.

Hartmut Seliger

Matthias Montenarh

Anja Frohlich

Michael Hinz

Jose Flavio Ramalho-Ortigao

Raoul Bader

Robert Haener

Yoon Jick Lee

Hans Häberlein

Erwin Happ

Hannelore Rosch

The invention relates to a composite system comprising at least one biodegradable blend, containing at least one biodegradable block copolyester urethane (PEU) and also at least one polyhydroxyalkanoate (PHA), possibly a filler comprising a polysaccharide and/or derivatives thereof and also possibly further biocompatible additives. Composite systems of this type are used for producing molded articles, molded parts or extrudates. Furthermore, the invention relates to possibilities for using the composite system.

Biodegradable composite system and the use thereof

The present invention concerns biodegradable linear polyester urethanes as well as biodegradable crosslinked polyester urethanes issuing from the linear polyester urethanes in such a way that they are crosslinked by diisocyanate bridges. By varying the degree of crosslinking it is possible to adjust the physical, chemical and biological properties in the crosslinked polyester urethane as defined by the invention in a targeted manner. In particular, it is possible to vary the rate of biodegradation of said crosslinked polyester urethane because the biological degradation takes place at a slower rate as the degree of crosslinking increases. Furthermore, the object of the invention is a method of producing the polyester urethanes as defined by the invention, as well as its application in the form of sheets or foils, shaped rubber articles, containers, packaging materials, in the field of galenic pharmacy; and in the form of adhesives and adhesive tapes and the like. Furthermore, the invention relates to polymer blends containing the polyester urethanes as defined by the invention.

Biodegradable polyester urethanes, method for the production and use thereof

Device and process for synthesizing macromolecules

Therapeutically utilizable oligonucleotides of the formulae I and II have been obtained by introduction of terminal 3'--3' and 5'--5' linkages. These compounds are stable to nucleases and suppress the biological function of nucleic acids.

Oligonucleotide analogs with terminal 3'-3' or 5'-5' internucleotide

Growing community of inventors

Elchingen-Thalfingen, Germany

Hartmut Seliger